

Supplementary Table S1. Predictive capacity of the MBDA score at multiple time-points

| MBDA score at: | %RRP (BL-Year 1) N=205† | %RRP (Year 1-Year 2) N=121 |
|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Baseline | Low/moderate vs high 1/33 (3%) vs 36/172 (21%) Sensitivity=0.97, specificity=0.19 NPV=0.97, PPV=0.21 | Low/moderate vs high 1/17 (6%) vs 16/104 (15%) Sensitivity=0.94, specificity=0.15 NPV=0.94, PPV=0.15 |
| Month 3 | Low vs moderate/high 1/33 (3%) vs 36/172 (21%) Sensitivity=0.97, specificity=0.19 NPV=0.97, PPV=0.21 | Low vs moderate/high 0/15 (0%) vs 17/106 (16%) Sensitivity=1.00, specificity=0.14 NPV=1.00, PPV=0.16 |
| Year 1 | NA | Low/moderate vs high 5/87 (6%) vs 12/34 (35%) Sensitivity=0.71, specificity=0.79 NPV=0.94, PPV=0.35 |
| Change of MBDA: | %RRP (BL-Year 1) N=205 | %RRP (Year 1-Year 2) N=121 |
| from BL to Month 3 | Low/moderate at BL OR high → low vs high → moderate OR persistent high 2/50 (4%) vs 35/155 (23%) Sensitivity=0.95, specificity=0.29 NPV=0.96, PPV=0.23 | NA |
| from BL to Year 1 | NA | Low/moderate at BL OR high → moderate/low vs persistent high 5/90 (6%) vs 12/31 (39%) Sensitivity=0.71, specificity=0.82 NPV=0.94, PPV=0.39 |
| from Month 3 to Year 1 | NA | Low at M3, OR moderate/high (M3) AND achieving low/moderate (Year1) vs moderate → high OR persistent high 5/88 vs (6%) 12/33 (36%) Sensitivity=0.71, specificity=0.80 NPV=0.94, PPV=0.36 |

†The same patient numbers and proportion of RRP (BL-Year 1) in low/moderate vs high groups according to the MBDA score at baseline or low vs moderate/high groups according to the MBDA score at Month 3 (the first two cells of the second column) does not mean that they are exactly the same patients in the respective groups. For more details see Figure 3A, left bar-graph.